Spots Global Cancer Trial Database for pdr001
Every month we try and update this database with for pdr001 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | NCT02740270 | Solid Tumors Lymphomas | GWN323 PDR001 | 18 Years - | Novartis | |
| Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | NCT03172936 | Solid Tumors an... | MIW815 PDR001 | 18 Years - | Novartis | |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | NCT04544111 | Thyroid Cancer Thyroid Cancer,... Papillary Thyro... Follicular Thyr... Hurthle Cell Tu... Poorly Differen... Hurthle Cell Th... | Trametinib Dabrafenib PDR001 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus | NCT03785496 | Histologically ... | PDR001 | 18 Years - | Yonsei University | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | NCT03891953 | Carcinoma, Non-... Melanoma Nasopharyngeal ... Microsatellite ... Triple Negative... | DKY709 PDR001 | 18 Years - | Novartis | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | NCT03499899 | Triple-negative... | LAG525 PDR001 Carboplatin | 18 Years - | Novartis | |
| A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | NCT03207867 | NSCLC, Non Smal... RCC, Renal Cell... Pancreatic Canc... Urothelial Canc... Head and Neck C... DLBCL, Diffused... MSS, Microsatel... TNBC, Triple Ne... Melanoma mCRPC, Metastat... | NIR178 PDR001 | 18 Years - | Novartis | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | NCT03176264 | Metastatic Colo... | PDR001 bevacizumab mFOLFOX6 | 18 Years - | Novartis | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | NCT03081494 | Metastatic Colo... | spartalizumab (... regorafenib | 18 Years - | Novartis | |
| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | NCT01351103 | Pancreatic Canc... BRAF Mutant Col... Melanoma Triple Negative... Head and Neck S... Cervical Squamo... Esophageal Squa... Lung Squamous C... | LGK974 PDR001 | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | NCT03499899 | Triple-negative... | LAG525 PDR001 Carboplatin | 18 Years - | Novartis | |
| Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | NCT03294694 | Metastatic Horm... HER2-Negative B... Metastatic Epit... | Ribociclib PDR001 Fulvestrant | 18 Years - | Dana-Farber Cancer Institute | |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | NCT03549000 | Non-small Cell ... Triple Negative... Pancreatic Duct... Colorectal Canc... Ovarian Cancer Renal Cell Carc... Metastatic Cast... | NZV930 PDR001 NIR178 | 18 Years - | Novartis | |
| Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | NCT02607813 | NSCLC Ovarian Cancer Melanoma Other Solid Tum... | LXH254 PDR001 | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | NCT03484923 | Melanoma | PDR001 LAG525 INC280 ACZ885 LEE011 | 18 Years - | Novartis | |
| Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | NCT03301896 | Solid Tumors | LHC165 PDR001 | 18 Years - | Novartis | |
| Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | NCT03111992 | Multiple Myelom... | PDR001 CJM112 LCL161 | 18 Years - | Novartis | |
| Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus | NCT03785496 | Histologically ... | PDR001 | 18 Years - | Yonsei University | |
| Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) | NCT04736485 | Gastric Cancer ... Resectable Carc... | perioperative t... | 18 Years - | Centre Francois Baclesse | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | NCT02325739 | Hepatocellular ... Solid Malignanc... | FGF401 PDR001 | 18 Years - | Novartis | |
| FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | NCT02325739 | Hepatocellular ... Solid Malignanc... | FGF401 PDR001 | 18 Years - | Novartis | |
| Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | NCT03668431 | Metastatic Colo... | Dabrafenib Trametinib PDR001 | 18 Years - | Massachusetts General Hospital | |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | NCT04544111 | Thyroid Cancer Thyroid Cancer,... Papillary Thyro... Follicular Thyr... Hurthle Cell Tu... Poorly Differen... Hurthle Cell Th... | Trametinib Dabrafenib PDR001 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | NCT04895748 | Carcinoma, Rena... | DFF332 RAD001 PDR001 NIR178 | 12 Years - | Novartis | |
| Phase I Study of PDR001 in Patients With Advanced Malignancies. | NCT02678260 | Advanced Malign... | PDR001 | 18 Years - | Novartis | |
| A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers | NCT02452268 | Metastatic and ... | NIZ985 PDR001 | 18 Years - | Novartis | |
| PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | NCT03064854 | Non-small Cell ... | PDR001 Cisplatin Gemcitabine Pemetrexed Carboplatin Paclitaxel Canakinumab | 18 Years - | Novartis | |
| Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments | NCT04058756 | Advanced Solid ... | PDR001 | 18 Years - | Novartis | |
| Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | NCT03111992 | Multiple Myelom... | PDR001 CJM112 LCL161 | 18 Years - | Novartis | |
| PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | NCT03064854 | Non-small Cell ... | PDR001 Cisplatin Gemcitabine Pemetrexed Carboplatin Paclitaxel Canakinumab | 18 Years - | Novartis | |
| Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT02403193 | Non-small Cell ... | PBF-509_80 mg PBF-509_160 mg PBF-509_320 mg PBF-509_640 mg Combo PBF-509 (... Combo PBF-509 (... Combo PBF-509 (... RP2D (PBF-509+P... Experimental: R... | 18 Years - | Palobiofarma SL | |
| Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | NCT02947165 | Breast Cancer Lung Cancer Hepatocellular ... Colorectal Canc... Pancreatic Canc... Renal Cancer | NIS793 PDR001 | 18 Years - | Novartis | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | NCT03172936 | Solid Tumors an... | MIW815 PDR001 | 18 Years - | Novartis | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | NCT02947165 | Breast Cancer Lung Cancer Hepatocellular ... Colorectal Canc... Pancreatic Canc... Renal Cancer | NIS793 PDR001 | 18 Years - | Novartis | |
| Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | NCT02740270 | Solid Tumors Lymphomas | GWN323 PDR001 | 18 Years - | Novartis | |
| PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities | NCT03693326 | Cancer Lung Cancer Met... Immunotherapy | PDR001 | 18 Years - | Asan Medical Center | |
| PDR001 + Panobinostat for Melanoma and NSCLC | NCT03982134 | Melanoma Non Small Cell ... | PDR001 Panobinostat | 18 Years - | University of Iowa | |
| A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | NCT01351103 | Pancreatic Canc... BRAF Mutant Col... Melanoma Triple Negative... Head and Neck S... Cervical Squamo... Esophageal Squa... Lung Squamous C... | LGK974 PDR001 | 18 Years - | Novartis | |
| A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | NCT03207867 | NSCLC, Non Smal... RCC, Renal Cell... Pancreatic Canc... Urothelial Canc... Head and Neck C... DLBCL, Diffused... MSS, Microsatel... TNBC, Triple Ne... Melanoma mCRPC, Metastat... | NIR178 PDR001 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
